

RECEIVED
CENTRAL FAX CENTER
DEC 12 2006

004

Appl. No. : 10/706,300
Filed : November 12, 2003

AMENDMENTS TO THE CLAIMS

WHAT IS CLAIMED:

1. (Currently Amended) An implant for treating glaucoma, comprising:
a body comprising material that includes a drug, said body having an inlet portion and an outlet portion, said inlet portion configured to reside in transport fluid from the anterior chamber of an eye to the outlet portion when the outlet portion is disposed in Schlemm's canal of the eye, said outlet portion having an outflow opening such that said body transports fluid from the anterior chamber to Schlemm's canal.
2. (Original) The implant of Claim 1, wherein said body is coated with said drug.
3. (Original) The implant of Claim 1, wherein said drug comprises heparin.
4. (Original) An implant for treating glaucoma, comprising:
a body having a bioactive agent in or on said body, said body having an inlet portion and an outlet portion, said inlet portion configured to transmit fluid from the anterior chamber to the outlet portion when the outlet portion is disposed in Schlemm's canal, said outlet portion having an outflow opening.
5. (Original) The implant of Claim 4, wherein said body is coated with said bioactive agent.
6. (Original) The implant of Claim 4, wherein said bioactive agent comprises heparin.
7. (Original) The implant of Claim 4, wherein said bioactive agent comprises TGF-beta.
8. (Original) The implant of Claim 4, wherein said bioactive agent comprises a gene.
9. (Original) The implant of Claim 4, wherein said bioactive agent comprises an anti-inflammatory drug.
10. (Original) The implant of Claim 4, wherein said bioactive agent comprises an intraocular pressure-lowering drug.
11. (Original) The implant of Claim 4, wherein said bioactive agent comprises a growth factor.

Appl. No. : 10/706,300
Filed : November 12, 2003

12. **(Original)** The implant of Claim 4, wherein said bioactive agent comprises an antiproliferative agent.

13. **(Original)** The implant of Claim 4, wherein said bioactive agent is loaded onto a surface of the outlet section.

14. **(Original)** The implant of Claim 4, further comprising a biodegradable material in or on said implant.

15. **(Original)** The implant of Claim 14, wherein the biodegradable material is selected from the group consisting of: poly(lactic acid), poly(ethylene-vinyl acetate), poly(lactic-co-glycolic acid), poly(D,L-lactide), poly(D,L-lactide-co-trimethylene carbonate), collagen, heparinized collagen, poly(caprolactone), poly(glycolic acid), and a copolymer.

16. **(Original)** The implant of Claim 4, wherein the outlet end further comprises a plurality of pillars at said outlet end.

17. **(Original)** The device of Claim 16, wherein the bioactive agent is in or on at least one of said pillars.

18. **(Original)** The implant of Claim 4, wherein said implant is at least partially coated with at least one polymer film that contains the bioactive agent, said polymer film permitting a delivery of a quantity of the bioactive agent to ocular tissues over time.

19.-45. **(Cancelled)**